Among NSCLC patients, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), EGFR, or STK11 mutations do not respond to ICIs, while KRAS, tumor protein P53 (TP53) mutants, and mesenchymal-to-epithelial transition factor (MET) gene exon 14 skipping mutations respond well to ICIs [110]. Here, KRAS is linked to non-small cell lung carcinoma.